If you have been reading about AOD9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-02-27. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Competitive antagonists are usually structurally similar to the active compound since they are structural analogues that have to bind to the same pocket. Examples of reversible competitive antagonists like antihistamines (Figure 1) compete with histamine (Figure 2) to bind to histamine receptors, blocking the allergic response by histamine. They are used in treating histamine-mediated allergies and allergic rhinitis. Irreversible competitive antagonists like phenoxybenzamine do not dissociate from alpha-adrenergic receptors. It is used to block the activity of alpha receptors in sympathetic pathway and is used in the treatment of paroxysmal hypertension and sweating resulting from pheochromocytoma and benign prostate hyperplasia.
Lawsuits against Merck & Co. regarding the marketing and use of Vioxx The landmark whistleblower case involving Neurontin (gabapentin) and off-label marketing: United States of America ex rel. David Franklin vs. Parke-Davis, Division of Warner-Lambert/Pfizer Investigations into conflict of interest and academic institutions by the US Senate Finance Committee, headed by Charles Grassley (R-Iowa) Investigations into the marketing of Vioxx to physicians by the United States House Committee on Oversight and Government Reform, headed by Henry A. Waxman Antitrust litigation involving Abbott Labs and their HIV/AIDS drug Norvir Lawsuits against Wyeth for the unethical promotion of the hormone replacement drug Premarin to women. Wyeth paid medical ghostwriters to author journal articles about the drug.
GLD-2 primarily stabilizes mRNAs that are translationally repressed as well as it strongly promotes bulk polyadenylation. Surprisingly, those functions seem to have little impact on dynamizing efficient target mRNA translation, as it is an efficient Poly(A) Polymerase which helps developing polyadenylation activity. This activity is stimulated by its interaction with a putative RNA-binding protein: GLD-3. It is proposed by some studies that GLD-3 stimulates GLD-2 by recruiting it to the RNA. If so, then bringing GLD-2 to the RNA by other means also should stimulate its activity. GLD-2, as a poly(A) polymerase (PAP) acts incorporating ATP at the 3' end of mRNAs in a template-independent manner. ==== Enzymatic activity: Polynucleotide adenylyltransferase activity ==== It has been discovered that this protein has a catalytic activity, in other words, it has the ability to increase the speed of chemical reactions which would not occur so fast. It is known to catalysis the following reaction (which requires the following cofactor: Mg(2+)): ATP + RNA(n) ⇄ diphosphate + RNA(n+1)
Giochi per il mio computer called the first episode professional product and an extremely compelling horror adventure. PCZeta said They Hunger has masterful use of lighting, creepy sound effects and ingenious level design. PC Player said They Hunger is the most acclaimed single-player Half-Life mod among the fan community. CNET Gamecenter placed it on its list of top 10 Half-Life mods, writing: "They Hunger is the best horror-themed first-person shooter since the original Blood." Planet Half-Life wrote about the first episode in 2000: "In short, the dark atmosphere is there, the weapon balance is right on, and the immersion is near-total." In 2006, they wrote: "Its sweet blend of ambience, satisfyingly intense close-quarters zombie combat (or SICQZC for short), and slick manner of horror panache make it a must-download." MegaGame noted the second episode as an excellent sequel to a remarkable game. .NetGamer called the map design and gameplay of They Hunger 2 spectacular and said it's a must-have for every Half-Life fan. GameSpot noted They Hunger 2 as Manke's current magnum opus. Level liked the second episode more than the first one. They said it's longer and more visually appealing. The levels were noted as very well crafted. Planet Half-Life said the second episode has "a tangibly different feel" and more emphasis on gunplay.
Sources: en.wikipedia.org
== Pharmacology == The enzymes do not reach the bloodstream in significant amounts and are presumed to largely stay at the point of injection until they are broken down by proteases. The two collagenases act synergistically by cleaving tropocollagen (the 'collagen molecule') at different points. AUX-I attacks the C- and N-termini, AUX-II cleaves amino acid bonds within the molecule. Small collagen fragments are broken down by both enzymes.
== Composition == Petroleum consists of a variety of liquid, gaseous, and solid components. Lighter hydrocarbons are the gases methane, ethane, propane and butane. Otherwise the bulk of the liquid and solids are largely heavier organic compounds, often hydrocarbons (C and H only). The proportion of light hydrocarbons in a petroleum mixture varies among oil fields. An oil well produces predominantly crude oil. Because the pressure is lower at the surface than underground, some of the gas will come out of solution and be recovered (or burned) as associated gas or solution gas. A gas well produces predominantly natural gas. However, because the underground temperature is higher than at the surface, the gas may contain heavier hydrocarbons such as pentane, hexane, and heptane ("natural-gas condensate", often shortened to condensate.) Condensate resembles gasoline in appearance and is similar in composition to some volatile light crude oils. The hydrocarbons in crude oil are mostly alkanes, cycloalkanes and various aromatic hydrocarbons, while the other organic compounds contain nitrogen, oxygen, and sulfur, and traces of metals such as iron, nickel, copper and vanadium. Many oil reservoirs contain live bacteria. The molecular composition of crude oil varies widely from formation to formation, but the proportion of chemical elements varies over fairly narrow limits as follows:
=== Pusha T's solo career and work relationship with GOOD Music === Before releasing any solo material, Pusha T signed in the autumn of 2010 to GOOD Music, a record label founded by West. That year, he appeared on multiple songs in West's GOOD Fridays series, rapped in the GOOD cypher at the BET Hip Hop Awards, and had two features on West's album My Beautiful Dark Twisted Fantasy. The creative partnership was fruitful; Pusha T became president of GOOD in 2015, and West had production credits on all of his commercially released albums until It's Almost Dry. Pusha T was publicly outspoken about not seeing eye-to-eye with West on politics and career moves multiple times. Among other examples, he expressed disagreement over West's support of Donald Trump and claimed to have different principles on music industry relationships. The relationship had completely deteriorated by late 2022, after West made statements widely condemned as antisemitic. Pusha T said the following in response to West's comments: "It's definitely affected me. It's been disappointing. As a Black man in America, there is no room for bigotry or hate speech. So yeah. It's been very disappointing, let's talk straight." In another interview, he said: "It's beyond [wild stuff] and it's nothing to tap dance around. It's wrong. Period." and "He's not speaking to me now. If you ain't with it, you ain't down. And I ain't with it. I'm not budging on that. I'm not with it." He also clarified that he was no longer the president of GOOD or affiliated with the label in any way.
Sources: en.wikipedia.org
Glutamatergic means "involving the release of, or activated by, glutamate". A glutamatergic agent (or drug) is a chemical that directly modulates the excitatory amino acid (glutamate/aspartate) system in the body or brain. Examples include:
5p partial monosomy syndrome Bloom syndrome Branchiootorenal syndrome 1 Cardiofaciocutaneous syndrome 4 Christianson syndrome Congenital disorder of glycosylation, type IIw Congenital myasthenic syndrome 2A Congenital myopathy 4A, autosomal dominant Congenital myopathy 4B, autosomal recessive Creatine transporter deficiency Cutis laxa, X-linked Ehlers-Danlos syndrome, Beasley-Cohen type Granulocytopenia with immunoglobulin abnormality Hereditary spastic paraplegia 23 and 51 Intellectual disability, autosomal recessive 5 Intellectual disability, X-linked 107, 58, and 61 Knobloch syndrome Marfan syndrome Mitochondrial DNA depletion syndrome 13 Nance-Horan syndrome Oculofaciocardiodental syndrome Otofaciocervical syndrome 1 Proximal myopathy with extrapyramidal signs Radioulnar synostosis-developmental delay-hypotonia syndrome Renpenning syndrome Seckel syndrome 9 Severe X-linked myotubular myopathy SIN3A-related intellectual disability syndrome due to a point mutation Symphalangism-brachydactyly syndrome Syndromic X-linked intellectual disability 14 Torsion dystonia 4 X-linked intellectual disability with marfanoid habitus XFE progeroid syndrome
=== Environment === Many environmental factors will be critical for the welfare and productivity of insect farms. These include: temperature, humidity/moisture, light cycles, oxygen levels, and stocking densities or other spatial features of the environment. For instance, larger cages and specific wavelengths of light are essential for the natural behaviors of adult black soldier fly breeders. Temperature and humidity must be carefully controlled or excess mortality, and putative welfare harms, will result for most insect species. Jagran raises housefly larvae for use as animal feed and report that humidity needs to be carefully controlled to avoid dehydrating or drowning the insects. Insects are poikilothermic, but maintaining an adequate temperature range remains important. For example, lethal overheating is a problem in black soldier fly and yellow mealworm larvae that are reared in dense aggregations within insulating substrates. Although many farmed insects are naturally gregarious, when stocking densities are too high this can cause lethal overheating, increase aggression and cannibalism, or result in altered development and different behavioral needs that may be challenging to fulfill on farms. For instance, some crickets may develop longer wings in an effort to fly far and escape overcrowded conditions on farms; the inability to escape these conditions reduces natural behavioral expression and results in reports of aggression and cannibalism, as stated by one producer: "...they'll bite each other, they'll eat each other".
A person who helps a patient work with others who have an effect on the patient's health, including doctors, insurance companies, employers, case managers, and lawyers. A patient advocate helps resolve issues about health care, medical bills, and job discrimination related to a patient's medical condition. (NCI) Peer review
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.